Education
About Us
Working with TipRanks
Follow Us
Seer (SEER)
NASDAQ:SEER
SEER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $2.63
Previous CloseN/A
Volume76.55K
Average Volume (3M)94.67K
Market Cap
$124.75M
Enterprise Value-$113.92M
Total Cash (Recent Filing)$239.72M
Total Debt (Recent Filing)$25.40M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 11, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding54,801,254
10 Day Avg. Volume82,260
30 Day Avg. Volume94,675
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.91
Enterprise Value/Revenue-7.51
Enterprise Value/Gross Profit-18.64
Enterprise Value/Ebitda1.25
Forecast
1Y Price Target
$3.00Price Target Upside49.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Commercial InitiativesSEER has experienced strong traction from its STAC program as sample volumes increased and service revenue grew by 28%.
Operational SuccessThe number of instruments shipped in the quarter matched the total for the entire previous year, demonstrating strong demand and operational performance.
Revenue Performance2Q revenue of $4.1M was approximately 8% ahead of $3.8M consensus, with strong product revenue of $2.7M despite the difficult macro for capital expenditure.
Bears Say
Government Funding UncertaintyRevenue guidance remains cautious due to uncertainty around government funding and US tariff policies affecting market visibility.
Instrument Sales DeclineSeer, Inc. saw a decline in product revenue driven by a decrease in instrument sales due to pressure on capital expenditure budgets and longer sales cycles.
Market ConditionsChallenging market conditions across Pharma and A&G continue to temper demand and weigh on the stock's performance.
Seer News
SEER FAQ
What was Seer’s price range in the past 12 months?
Seer lowest stock price was $1.58 and its highest was $2.63 in the past 12 months.
What is Seer’s market cap?
Seer’s market cap is $124.75M.
When is Seer’s upcoming earnings report date?
Seer’s upcoming earnings report date is Nov 11, 2025 which is in 95 days.
How were Seer’s earnings last quarter?
Seer released its earnings results on Aug 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.042.
Is Seer overvalued?
According to Wall Street analysts Seer’s price is currently Undervalued.
Does Seer pay dividends?
Seer does not currently pay dividends.
What is Seer’s EPS estimate?
Seer’s EPS estimate is -0.32.
How many shares outstanding does Seer have?
Seer has 54,801,254 shares outstanding.
What happened to Seer’s price movement after its last earnings report?
Seer reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went down -2.427%.
Which hedge fund is a major shareholder of Seer?
Currently, no hedge funds are holding shares in SEER
Seer Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (49.25% Upside)
$3.00 (49.25% Upside)
Hedge Fund Trend
Decreased
By 274.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $83.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.73%
12-Months-Change
Fundamentals
Return on Equity
-25.25%
Trailing 12-Months
Asset Growth
-17.70%
Trailing 12-Months
Company Description
Seer
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
SEER Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as strong revenue growth, successful product launches, and strategic partnerships. However, challenges in the form of decreased gross margins, high operating expenses, and external economic pressures were also noted. Overall, the positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all SEER earnings summariesSEER Stock 12 Month Forecast
Average Price Target
$3.00
▲(49.25% Upside)
Technical Analysis
ADC Therapeutics
―
Kalaris Therapeutics
―
Silence Therapeutics
―
4D Molecular Therapeutics
―
Vor Biopharma
―
Ownership Overview
5.85% Insiders
8.44% Mutual Funds
1.81% Other Institutional Investors
79.38% Public Companies and
Individual Investors